SOCMA Offers Support for Free Trade Pacts with South Korea, Panama, and Colombia - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

SOCMA Offers Support for Free Trade Pacts with South Korea, Panama, and Colombia


ePT--the Electronic Newsletter of Pharmaceutical Technology

The Society of Chemical Manufacturers and Affiliates (SOCMA) issued its support this week of the passage of pending free-trade agreements (FTA) with South Korea, Panama and Colombia by two Congressional committees. SOCMA is the US-based trade association representing custom and batch manufacturers, including contract manufacturers of fine chemicals, pharmaceutical intermediates, and active pharmaceutical ingredients.

SOCMA reported that all three trade agreements were backed by the House Ways and Means and Senate Finance Committees. The Senate panel approved the Korea trade pact with an extension of expanded Trade Adjustment Assistance (TAA) and the House approved a similar agreement without the language. TAA, which provides training to assist unemployed workers in retooling and find new job opportunities, was a subject of debate in the negotiations, according to a July 11, 2011, SOCMA press release.

The Senate Finance Committee approved its recommendations for passage of the three free-trade pacts as part of mock markup. Committee mock markups are the standard way Congress weighs in on the administration's FTAs negotiated under fast-track authority, which prohibits amendments to the final implementing bills. Following administration review of any amendments that the Senate Finance and House Ways and Means Committees approve on the draft implementing bills, final versions of the implementing bills will be submitted to Congress for an up-or-down vote, according to a July 7, 2011, US Senate Finance Committee press release. The House Ways and Means Committee also reported on its support for the three FTAs, according to a July 7, 2011, press release.

“We appreciate the support of both committees in moving these deals forward and urge Congress to come to a bicameral, bipartisan conclusion to include trade adjustment assistance (TAA) with these three pending agreements,” said SOCMA President and CEO Lawrence D. Sloan, in the SOCMA press release. 

In a letter earlier this month to Senate Finance Committee Chair Max Baucus (D-MT) and ranking member Orrin Hatch (R-UT), Sloan outlined the benefits of approving the FTAs to chemical manufacturers, saying that the Colombia deal, in particular, would boost the chemical industry. “The benefits to chemical manufacturers as a result of approving FTAs are real,” Sloan said. “For example, the chemical industry paid $480 million in duties to Colombia between 2008 and 2010, the most of any other exporting sector. The FTA with Colombia would eliminate 80% of these duties once the agreement becomes effective and would eliminate the rest within 10 years. Clearly, this pending FTA will bring immediate relief to chemical manufacturing companies, allowing them to expand sales to this important market,” he said.

Although supportive of the Congressional committees' advocacy for the FTAs, Sloan cautioned against further Congressional delay in approving these pacts and other such agreements. “Our country’s failure to approve these agreements is hurting us in other ways,” said Sloan in the press statement. “There is a growing belief among key trading partners that if America is unable to pass its three trade agreements, the Trans-Pacific Partnership (TPP) negotiations this year will be placed in doubt, which will further diminish the US’s ability to gain advantage within the giant growing markets in Asia.”

The TPP Agreement is an Asia-Pacific regional trade agreement currently being negotiated among the United States and eight other partners. The United States’ TPP negotiating partners are Australia, Brunei, Chile, Malaysia, New Zealand, Peru, Singapore, and Vietnam.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
18%
To all process for new products only
14%
To select process for new products only
23%
To select processes for both new and legacy products
20%
Do not use QbD
25%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Inadequate Access to Medicines Puts EU at Risk
FDA Offers Insight on QbD for Modified-Release Products
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
FindPharma Custom Search
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here